The Combined Role of Herbal Therapy in the Prevention of Urinary Tract Infections During Prostate Biopsy

##plugins.themes.bootstrap3.article.main##

Г. В. Ільяш
В. П. Глухов
Н. Е. Авадієва
С. К. Беджанян
І. О. Гудіма
А. С. Поляков

Abstract

Prostate biopsy is a routine method for diagnosing prostate cancer. However, there are a number of serious complications associated with this procedure, and especially development of infection.

The objective. Evaluation of the effectiveness of complex herbal therapy in the prevention of infectious complications in patients exposed to prostate biopsy.

Materials and methods. The study included 40 patients aged 48 to 69 years who underwent prostate biopsy. Patients with chronic prostatitis (category 4 NIH) were divided into two groups. Patients in the comparison group limited to standard antibiotic therapy, and the patients of the main group additionally received Canephron® N. The efficacy of the therapy was evaluated at 1, 2 and 6 months after the start of treatment by the dynamics of leukocyte count in prostate secretion and bacterial contamination, prostate– specific atigen (PSA) level, questionnaire data, ultrasound and urodynamic survey methods.

Results. The level of PSA compared to baseline data, decreased by 56.9 % in the comparison group and by 67.6 % in the main group (p<0.05). A clinically significant bacterial titer and an increase in the number of leukocytes more than10 in sight, were registered in the comparison group in two times more often, than in patients of the main group.

Conclusion. The results of the study make it possible to recommend for patients with chronic prostatitis of category 4 NIH the prescription of Canephron N.

##plugins.themes.bootstrap3.article.details##

How to Cite
Ільяш, Г. В., Глухов, В. П., Авадієва, Н. Е., Беджанян, С. К., Гудіма, І. О., & Поляков, А. С. (2019). The Combined Role of Herbal Therapy in the Prevention of Urinary Tract Infections During Prostate Biopsy. Health of Man, (3), 64–66. https://doi.org/10.30841/2307-5090.3.2019.185672
Section
Urology
Author Biographies

Г. В. Ільяш, Rostov State Medical University

Anna V. Ilyash,

Clinic of Urology

В. П. Глухов, Rostov State Medical University

Vladimir P. Gluhov,

Department of Urology and Reproductive Health with a Course of Pediatric Urology-andrology

Н. Е. Авадієва, Rostov City Polyclinic No 10

Nadezhda E. Avadiyeva,

urologist

С. К. Беджанян, Rostov State Medical University

Saro K. Bedzhanyan,

Department of Urology and Reproductive Health with a Course of Pediatric Urology-andrology

І. О. Гудіма, Rostov State Medical University

Irina A. Gudima,

Department of Microbiology and Virology No 1

А. С. Поляков, Rostov State Medical University

Andrey S. Polyakov,

Department of Urology and Reproductive Health with a Course of Pediatric Urology-andrology

References

Webb NR, Woo HH. Antibioti c prophylaxis for prostate biopsy. BJU Int. 2002;89(8):824-8.

Zani EL, Clark OA, Rodrigues Netto N Jr. Anttbiottc prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev. 2011;(5):CD006576.

de Jesus CM, Correa LA, Padovani CR. Complications and risk factors in transrectal ultrasound-guided prostate biopsies. Sao Paulo Med J. 2006;124(4):198-202.

Miura T, Tanaka K, Shigemura K, Nakano Y, Takenaka A et al. Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: Report of four cases and review of the literature. International Journal of Urology 2008;15(5):457-459.

Борисов В.В., Гордовская Н.Б., Шилов Е.М. Фитотерапия препаратом Канефрон Н в нефрологической практике: настоящее и перспективы. Клиническая нефрология. 2010;(6):39-42.

Кульчавеня Е.В., Бреусов А.А. Профилактика рецидивов хронического бактериального простатита. Урология. 2014;(4):50-52.

Неймарк А.И., Сульдина А.П., Батанина И.А. Применение препарата Канефрон Н в комплексном лечении хронического пиелонефрита. Российский медицинский журнал. 2014;20(6):23-26.

Okegawa T, Kinjo M, Ohta M, Miura I, Horie S et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol. 2003;10(4):201-6.

Xie GS, Lyv JX, Li G, Yan CY, Hou JQ et al. Prostate-specific Antigen Density Variati on Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy. Chin Med J (Engl). 2016;129(15):1800-4. doi: 10.4103/0366-6999.186635